Market Myths and Assumptions: Examining the Transnational Politics of Access to Medicines Campaigning in Central America

  title={Market Myths and Assumptions: Examining the Transnational Politics of Access to Medicines Campaigning in Central America},
  author={Angelina Snodgrass Godoy},
  journal={Studies in Comparative International Development},
  • A. Godoy
  • Published 15 May 2015
  • Political Science
  • Studies in Comparative International Development
In recent years, intellectual property rights protections have increased in Central America. Transnational access to medicines campaigns focused particular attention on the public health implications of these protections in the context of debates around the ratification of the US-Central America Free Trade Agreement (CAFTA), but these efforts did not lead to long-term engagement with intellectual property and access questions by local health activists. This paper explores differences in… 
The 13th Round: Article 39(3) TRIPS and the struggle over “Unfair Commercial Use”
The Treaty on Trade‐Related Aspects of Intellectual Property Rights (TRIPS) was the first international agreement to provide for some form of protection for regulatory information submitted by
CIFRA: Challenging the ICT Patent Framework for Responsible Innovation. D4.4: Policy Paper on potential new framings, identifying needs for changing the current IPR regime relevant for ICT industries
The correlation between measures associated with excessive patent fragmentation/proliferation and patent lags in the ICT industry during the period 1990-2012 is explored.


Balancing Wealth and Health: The Battle over Intellectual Property and Access to Medicines in Latin America
Introduction 1. Pharmaceutical Intellectual Property Rights Protection and Access to Medicines in Ecuador: State Sovereignty and Transnational Advocacy Networks 2. The Recursivity of Global Lawmaking
Of Medicines and Markets: Intellectual Property and Human Rights in the Free Trade Era
Central American countries have long defined health as a human right. But in recent years regional trade agreements have ushered in aggressive intellectual property reforms, undermining this
Four Lessons for Developing Countries from the Trade Negotiations Over Access to Medicines
After the Agreement on the Trade-Related Aspects of Intellectual Property Rights (TRIPS) came into operation in 1995 developing countries have found themselves in a process of continual negotiation
Implications of bilateral free trade agreements on access to medicines.
  • C. Correa
  • Political Science
    Bulletin of the World Health Organization
  • 2006
A recent new wave of free trade agreements requires even higher levels of intellectual property protection for medicines than those mandated by that Agreement, which further limit the competition of generic products.
International politics and primary health care in Costa Rica.
  • L. Morgan
  • Political Science
    Social science & medicine
  • 1990
Private Power, Public Law: The Globalization of Intellectual Property Rights
Susan K. Sell's book shows how power in international politics is increasingly exercised by private interests rather than governments. In 1994 the WTO adopted the Agreement on Trade-Related Aspects
Consensus and Coercion: Primary Health Care and the Guatemalan State
During the 1970s international and bilateral development agencies actively began promoting and financing comprehensive primary health care (PHC) programs in underdeveloped countries. The stated goal
Harmonization and its Discontents: A Case Study of TRIPS Implementation in India's Pharmaceutical Sector
In 2005, India amended its patent law to provide product patents on medicines, to comply with the WTO’s TRIPS Agreement. In order to mitigate the impact on access to medicines, India at the same time
Intellectual property and access to medicines: an analysis of legislation in Central America.
Comparisons of the countries that are part of the United States-Dominican Republic-Central America Free Trade Agreement (DR-CAFTA) suggest that industrialized countries and the pharmaceutical industry are using more tactics than just trade agreements to push for increased IP protection and that the process of national legislation is a valid arena for confronting public health needs to those of the industry.
Changing drug markets under new intellectual property regimes: the view from Central America.
It is found that even without the influence of intellectual property, drug pricing in the region was often unpredictable and that lower cost was not the only motivation driving governments' purchasing decisions.